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Background: Caspase-3 (CASP-3) is a primary effector CASP that 
executes programmed cell death, and it plays an important role in the 
development and progression of cancer. Polymorphisms in the CASP-
3 gene may inﬂuence CASP-3 production and/or activity, thereby 
modulating the susceptibility to lung cancer. To test this hypothesis, we 
investigated the association between CASP-3 polymorphisms and the 
risk of lung cancer in a Korean population. 
Methods: We ﬁrst screened single nucleotide polymorphisms (SNPs) 
in the CASP-3 gene by direct sequencing of genomic DNA samples 
taken from 27 healthy Korean individuals. We selected identiﬁed SNPs 
based on their frequency, linkage disequilibrium (LD) status and haplo-
type tagging status, and then genotyped the selected SNPs in 582 lung 
cancer patients and 582 healthy controls who were frequency matched 
for age and gender. 
Results: We identiﬁed eight SNPs: six known SNPs (-928A>G, 
246C>T, 829C>A, 1143G>C, 17532A>C and 20541C>T); and two 
novel SNPs (77G>A and 163G>T). Individuals with at least one variant 
allele of the -928A>G, 77G>A and 17532A>C polymorphisms were at 
a signiﬁcantly decreased risk for lung cancer in comparison to the carri-
ers with each homozygous wild-type allele [adjusted odds ratio (OR) = 
0.79, 95% conﬁdence interval (CI) = 0.62-1.00, P = 0.05; adjusted OR 
= 0.78, 95% CI = 0.61-0.99, P = 0.04; and adjusted OR = 0.74, 95% 
CI = 0.58-0.95, P = 0.02, respectively). Consistent with the results of 
genotyping analysis, the GAGC haplotype carrying the variant allele at 
all of the -928A>G, 77G>A, and 17532A>C loci was associated with a 
signiﬁcantly decreased risk of lung cancer compared to the AGGA hap-
lotype carrying no variant alleles at the three loci (adjusted OR = 0.66, 
95% CI = 0.51-0.86, P = 0.002 and Bonferroni corrected P = 0.008). 
Conclusions: These results suggest that the CASP-3 polymorphisms 
and their haplotypes contribute to the genetic susceptibility to lung 
cancer.
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Background: Improved early detection remains the most promising 
method of improving patient survival from lung cancer, and is a realis-
tic goal in the short term. This study reports the ﬁndings of a large scale 
trial evaluating a novel, fully automated method of DNA cytometry on 
sputum to detect lung cancer.
Methods: Over a period of 18 months, 1235 patients clinically suspi-
cious of having lung cancer were recruited into a multinational valida-
tion trial of the LungSign™ sputum test. Induced sputum was collected 
at the time of initial presentation, ﬁxed and treated with dithiothreitol 
(DTT). Papanicolaou stained smears were prepared and analysed by 
conventional cytology. Monolayer cytospin slides were prepared and 
stained using the Feulgen-thionin method. Cytospin slides were scored 
using LungSign, a test that uses a fully automated computerised DNA 
cytometry system to analyze thousands of epithelial cell nuclei to gen-
erate a measure associated with malignancy.
Results: Of the 1123 patients analysed, 370 proved to have lung cancer 
(prevalence 33%). The LungSign test provided an ROC “area under 
the curve” value of 0.692, and for a speciﬁcity of 91% it detected 40% 
of all lung cancers (Figure 1). Results were similar for all lung cancer 
histological types, as well as early (up to 1b) and later (stage 2a and 
above) stages. Conventional cytology detected 16% of cancers with a 
speciﬁcity of 99%. Approximately 12% of cytospins contained insuf-
ﬁcient epithelial cells for cytometric analysis. The inadequacy rate for 
conventional cytology was 43%.
Conclusions: In a high risk population, the LungSign test provides an 
effective means of detecting those patients most likely to have lung 
cancer. It is a continuous measure, permitting different cut points to be 
set. This ﬂexibility allows the test to be used in multiple contexts such 
as screening patients for lung cancer or evaluating suspicious lesions 
detected on CT, thereby directing efﬁcient use of other, more expensive 
and invasive diagnostic modalities.
Figure 1; ROC curve for the LungSign score, with conventional cytology 
(circle). Sensitivity and specificity standard error bars representing one stan-
dard deviation are shown.
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Background: Pre-clinical studies have shown that the majority of 
NSCLC have decreased expression of prostacyclin synthase (PGIS) and 
genetically modiﬁed mice with selective pulmonary PGIS overexpres-
sion are chemoprevented from developing lung cancer in a variety of 
models, including cigarette smoke exposure. Based on these promising 
results, a multi-center, double-blind, placebo controlled, phase II trial 
of iloprost (an oral prostacyclin analogue) in subjects at increased risk 
for lung cancer was initiated and continues to enroll.
Methods: Subjects are selected for the trial if they meet the follow-
ing criteria: current or former smoker (> 20 pack years); at least mild 
cytologic atypia on sputum cytology; no previous history of cancer. 
Fluorescent bronchoscopy is then performed with 6 standard sites biop-
sied, along with all other abnormally appearing areas. Subjects are then 
randomized to iloprost (in escalating doses) or placebo for 6 months 
and then undergo a repeat ﬂuorescent bronchoscopy with repeat biopsy 
of all the central airway areas sampled on the ﬁrst bronchoscopy. The 
primary endpoints for the study are bronchial histology and Ki-67 
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labeling index. Additional markers in the eicosanoid pathway are also 
being analyzed. 
Results: To date, a total of 119 subject have been enrolled in the trial 
(the majority of these at the University of Colorado, n=82), with the in-
vestigators remaining blinded in terms of treatment groups. Fluorescent 
bronchoscopy was able to successfully identify areas of mild dysplasia 
or worse in the majority of patients (90/119, 76%). A total of 17 (14%) 
patients had normal bronchial epithelium at all biopsy sites. A wide 
range of endobronchial pathology has been observed in the biopsies, 
with average baseline histology being signiﬁcantly elevated in current 
smokers. When biopsy sites are matched from the ﬁrst and second 
bronchoscopies, changes in histologic grade have been observed, with 
more individual sites showing improvement (n=116) than progression 
(n=72). The subjects are all being scored on histologic outcomes and 
there have been subjects with partial responses, stable disease, and 
progression. In the subset of subjects with Ki-67 analysis (n=49), a sig-
niﬁcant increase in labeling index was associated with smoking status 
(current > former, p=0.006) and worsening histologic grade (p<0.001). 
Immunohistochemical analyses for other markers in the eicosanoid 
pathway (including COX-2, mPGES, PGIS) are currently in progress. 
Conclusions: The iloprost chemoprevention trial continues to progress 
and has proven that our recruitment model can enrich for a population 
of subjects with endobronchial dysplasia. Results are still blinded. The 
treatment has been well tolerated and histologic improvement has been 
observed at speciﬁc biopsy sites in many of the subjects. Analysis of 
endobronchial biopsies for primary and secondary endpoints continues, 
and we are assessing different methodologies for evaluating clinical 
responses in chemoprevention trials (particularly those that could serve 
as a framework for current and future trials).
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Background: Patients at high-risk for the development of lung cancer 
frequently harbor atypical airway epithelium (bronchial dysplasia). 
These lesions are believed to be precursors of invasive lung cancer, 
especially squamous type. However, previous studies of the natural his-
tory of these lesions have been limited by small numbers of specimens 
and short periods of follow-up. We performed an exhaustive analysis 
of all patients enrolled in Colorado SPORE bronchoscopy protocols 
who underwent multiple bronchoscopies to characterize the long-term 
outcome of these lesions.
Methods: SPORE tissue bank records of histologic diagnosis, date of 
bronchoscopy and biopsy site for 121 patients (2,711 biopsies from 
720 unique biopsy sites), who had between two and eight bronchosco-
pies over as many as 11 years were collected. Within subjects, biopsy 
sites from different bronchoscopies were matched and each site was 
classiﬁed into progression, persistent or regression groups. Each site 
was assigned an initial diagnosis according to WHO classiﬁcation 
criteria. Progression, persistence and regression rankings were assigned 
according to whether the biopsy site showed change, or lack thereof, 
from the initial diagnosis to either of four diagnosis groups deﬁned 
as: Non-dysplastic (normal, basal cell hyperplasia and squamous 
metaplasia without atypia); Dysplastic (mild, moderate and severe); 
Carcinoma-in-situ and Invasive carcinoma. In addition to progression 
score, individual bronchoscopies were scored for dysplasia index (DI), 
deﬁned as the number of dysplastic biopsies (including CIS) divided 
by the total number of biopsies per bronchoscopy. Thirty patients with 
multiple brochoscopies had cancer diagnosed at some point during their 
enrollment. In analyses of relationships between bronchial histology 
and development of invasive cancer, an additional 28 patients with a 
single pre-carcinoma bronchoscopy were included.
Results: High grade (HGD: moderate, severe dysplasia and CIS) bron-
chial lesions were more frequently persistent than low grade (LGD: 
mild) lesions (68.5% vs 43.7%, respectively; Chi-square <0.001). 
In addition, both initial and mean DI was higher in persistent versus 
non-persistent (regression) groups for HGD and LGD groups. An-
giogenic squamous dysplasias (ASDs), a subset of dysplastic lesions, 
similarly showed increased persistence of HGD versus LGD lesions 
but additionally showed increased length of persistence in HGD-ASDs 
as compared non-ASD HGDs (25.5 vs. 17.1, respectiviely; p=0.024). 
A similar, non-signiﬁcant trend toward increased length of persistence 
was seen for LGD-ASDs versus non-ASD LGDs. A trend toward 
increased persistence of HGD lesions in patients with all types of 
NSCLC versus no carcinoma patients (80% vs. 65%) was found, and 
this percentage was even higher, though still not statistically differ-
ent, for the subset of patients with squamous cell carcinoma (85%). In 
addition, a trend toward increased mean DI in squamous cell carcinoma 
versus no carcinoma was seen (43% vs 31%).
Conclusions: Analysis of high risk patients undergoing multiple 
bronchoscopies shows a relationship between persistence and degree of 
atypia in bronchial dysplasia. An increase in the length of persistence 
is associated with presence of ASD histology. An association between 
squamous cell carcinoma development and high DI and/or persistence 
of HGD is suggested. These data support the role of bronchial dyspla-
sias as pre-malignant lesions in non-small cell lung cancer.
A7-06 Prevention & Early Detection, Mon, 13:45 - 15:30
The prevalence and persistence of premalignant lesions: a report of 
a high risk lung cancer cohort
Reid, Mary E.1 Jayaprakash, Vijayvel1 Menezes, Ravi1 Natarajan, Raj1 
Loewen, Gregory2 
1 Roswell Park Cancer Institute, Buffalo, NY, USA 2 Sacred Heart Medi-
cal Center, Spokane, WA, USA 
Background: Lung cancer causes more deaths than all of the other ma-
jor cancers combined with little improvement in the survival rate over 
the last 25 years. While premalignant lesions for central airway have 
been identiﬁed, the natural history of these lesions is unclear, especially 
for metaplastic lesions. Lung cancer screening of high-risk subjects 
with autoﬂuorescent bronchoscopy (AFB) can reliably detect the pre-
malignant lesions that are precursors to squamous cell carcinoma. 
Methods: A cohort of 350 patients underwent AF bronchoscopy 
(AFB) screening based on lung cancer risk factors at the Lung Cancer 
Screening Clinic at the Roswell Park Cancer Institute in Buffalo NY 
